4SC AG was granted a fundamental composition of matter patent for 4SC-208 for the US
. Patent provides United States (US) market exclusivity until 2033 Formal preclinical testing of 4SC-208 has already s…
. Patent provides United States (US) market exclusivity until 2033 Formal preclinical testing of 4SC-208 has already s…
4SC AG (4SC, FSE Prime Standard: VSC) today published the financial results of the 4SC Group for the financial year ende…
4SC AG (Frankfurt, Prime Standard: VSC), a biotechnology company for the research and development of targeted small mole…
4SC AG (Frankfurt, Prime Standard: VSC), a discovery and development company of targeted small molecule drugs for cancer…
4SC AG (Frankfurt, Prime Standard: VSC), a discovery and development company of targeted small molecule drugs for autoim…
4SC AG (Frankfurt, Prime Standard: VSC), a discovery and development company of targeted small molecule drugs for cancer…
4SC AG (Frankfurt, Prime Standard: VSC), a discovery and development company of targeted small molecule drugs for autoim…
4SC AG (Frankfurt, Prime Standard: VSC), a discovery and development company of targeted small molecule drugs for autoim…
4SC AG (Frankfurt, Prime Standard: VSC), a discovery and development company of targeted small molecule drugs for autoim…
4SC AG (Frankfurt, Prime Standard: VSC), a discovery and development company of targeted small molecule drugs for autoim…